Abstract
Background and Objectives: To establish the feasibility of sentinel lymph node (SLN) identification in patients with stage IB1 invasive cervical cancer. Methods: Selected patients with cervical cancer scheduled for radical hysterectomy with bilateral pelvic lymphadenectomy underwent SLN detection. Preoperatively, 1 mCi of technetium-99 (99Tc) was injected into four points of the superficial cervical stroma around the tumor. Intraoperatively, the patients underwent gamma-probe-guided lymphatic mapping, and patent blue dye was injected into the same points as the 99Tc. Results: Of the 12 eligible patients, 11 (92%) had at least one SLN detected. Seven (64%) patients had SLNs detected by intraoperative lymphoscintigraphy and the blue-dye technique, 3 (27%) by intraoperative lymphoscintigraphy, and 1 (9%) by the blue-dye technique only. Intraoperatively, 22 SLNs were detected: 9 (41%) by lymphoscintigraphy, 7 (32%) by lymphoscintigraphy and the blue-dye technique, and 6 (27%) by the blue-dye technique only. Six patients (54.5%) had bilateral SLNs. Sensitivity, specificity, positive predictive value, and negative predictive value for SLN detection were 100%, 80%, 33%, and 100%, respectively. There were no false-negative results. Conclusions: In this small cohort of patients, the combination of 99Tc and patent blue dye was safe and feasible for the detection of SLNs in early-stage cervical cancer. This study investigates the sentinel lymph node technique in patients with stage IB1 cervical cancer.
Keywords: Sentinel lymph node (SLN), cervical cancer, patent blue dye, technetium
Current Cancer Therapy Reviews
Title: Sentinel Lymph Node Identification in Patients with Stage IB1 Invasive Cervical Carcinoma
Volume: 3 Issue: 3
Author(s): Ricardo dos Reis, Eduardo Belmonte Tavares, Beatriz Amaral, Heleusa Ione Monego, Marcia Binda, Valentino Magno, Waldemar Rivoire, Maria Isabel Edelweiss and Edison Capp
Affiliation:
Keywords: Sentinel lymph node (SLN), cervical cancer, patent blue dye, technetium
Abstract: Background and Objectives: To establish the feasibility of sentinel lymph node (SLN) identification in patients with stage IB1 invasive cervical cancer. Methods: Selected patients with cervical cancer scheduled for radical hysterectomy with bilateral pelvic lymphadenectomy underwent SLN detection. Preoperatively, 1 mCi of technetium-99 (99Tc) was injected into four points of the superficial cervical stroma around the tumor. Intraoperatively, the patients underwent gamma-probe-guided lymphatic mapping, and patent blue dye was injected into the same points as the 99Tc. Results: Of the 12 eligible patients, 11 (92%) had at least one SLN detected. Seven (64%) patients had SLNs detected by intraoperative lymphoscintigraphy and the blue-dye technique, 3 (27%) by intraoperative lymphoscintigraphy, and 1 (9%) by the blue-dye technique only. Intraoperatively, 22 SLNs were detected: 9 (41%) by lymphoscintigraphy, 7 (32%) by lymphoscintigraphy and the blue-dye technique, and 6 (27%) by the blue-dye technique only. Six patients (54.5%) had bilateral SLNs. Sensitivity, specificity, positive predictive value, and negative predictive value for SLN detection were 100%, 80%, 33%, and 100%, respectively. There were no false-negative results. Conclusions: In this small cohort of patients, the combination of 99Tc and patent blue dye was safe and feasible for the detection of SLNs in early-stage cervical cancer. This study investigates the sentinel lymph node technique in patients with stage IB1 cervical cancer.
Export Options
About this article
Cite this article as:
Ricardo dos Reis , Eduardo Belmonte Tavares , Beatriz Amaral , Heleusa Ione Monego , Marcia Binda , Valentino Magno , Waldemar Rivoire , Maria Isabel Edelweiss and Edison Capp , Sentinel Lymph Node Identification in Patients with Stage IB1 Invasive Cervical Carcinoma, Current Cancer Therapy Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339407781368332
DOI https://dx.doi.org/10.2174/157339407781368332 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Management of Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Current Immunology Reviews (Discontinued) Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology Voltage-Gated Calcium Channels as Targets for the Treatment of Chronic Pain
Current Drug Targets - CNS & Neurological Disorders In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH<sub>2</sub>Ph)]Br
Anti-Cancer Agents in Medicinal Chemistry A Comprehensive Review on Pharmacology and Toxicology of Bioactive Compounds of <i>Lagerstroemia Speciosa(L.</i>) Pers.
Current Traditional Medicine Computational and Synthetic Biology Approaches for the Biosynthesis of Antiviral and Anticancer Terpenoids from <i>Bacillus subtilis</i>
Medicinal Chemistry Neurological Involvement in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) Ghrelin: New Insight to Mechanisms and Treatment of Postoperative Gastric Ileus
Current Pharmaceutical Design Microemulsions for Colorectal Cancer Treatments. General Considerations and Formulation of Methotrexate
Mini-Reviews in Medicinal Chemistry Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?
Current Medicinal Chemistry Antiviral Activities of Human Host Defense Peptides
Current Medicinal Chemistry EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer
Current Drug Targets Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets Articulating A Rights-Based Approach to HIV Treatment and Prevention Interventions
Current HIV Research Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design Quantum Dots in the Therapy: Current Trends and Perspectives
Mini-Reviews in Medicinal Chemistry Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Polymer Membrane and Cell Models for Drug Discovery
Combinatorial Chemistry & High Throughput Screening Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Phosphatidylinositol 3-kinase Signaling as a Therapeutic Target for Cervical Cancer
Current Cancer Drug Targets